Navigation Links
Cell Therapeutics, Inc. Announces Exercise of Overallotment
Date:7/23/2009

filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, New York 10020, or by calling (212) 356-0549.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect the actual future results of the Company and the trading price of securities of the Company. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
2. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
3. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
4. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
10. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
11. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... October 30, 2014 Avure Technologies celebrates a ... the newest member of its fleet of high volume High ... an anniversary as we return to PackExpo this year, which ... in Las Vegas,” said Jeff Williams, CEO at Avure. “Sales ... we’re pleased to be meeting the challenges of market demand ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... RIDGE, N.J. , Oct. 30, 2014  Regado ... that it will hold a conference call and live ... a.m. EST to discuss its third quarter 2014 financial ... the conference call by dialing (888) 347-1165 for domestic ... call will be webcast live under the investor relations ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... Raptor,Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC ... development division, Bennu,Pharmaceuticals Inc. ("Bennu"), has acquired ... the exclusive worldwide license to EC,Cysteamine, developed ... San Diego, School of Medicine, by way ...
... Dec. 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: ... molecular diagnostic,tests for the early detection of ... it has started collecting patient samples,for clinical ... development,ColonSentry(TM)., In June 2006, GeneNews presented ...
... is a new drug being,studied to prevent fractures in ... 3 clinical trial using denosumab were presented,Friday evening at ... from the Seattle Cancer Care Alliance., Denosumab is ... -- specialized cells that break down bone. Because it ...
Cached Biology Technology:Raptor Pharmaceuticals Acquires Orphan Clinical Program 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 3Raptor Pharmaceuticals Acquires Orphan Clinical Program 4Raptor Pharmaceuticals Acquires Orphan Clinical Program 5Raptor Pharmaceuticals Acquires Orphan Clinical Program 6GeneNews initiates patient sample accrual for validation studies of colon cancer blood test 2GeneNews initiates patient sample accrual for validation studies of colon cancer blood test 3New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2
(Date:10/29/2014)... Researching the safety of nanoparticles is all the rage. ... topic, examining the question of whether titanium dioxide nanoparticles ... into the body, whether carbon nanotubes from electronic products ... to be or whether nanoparticles in food can get ... Public interest is great, research funds are flowing – ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3MSU partners with Detroit to investigate death scenes 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2
... , , WALL, N.J., Dec. ... BKYI), a leader in finger-based biometric identification solutions, ... world,s most respected security publications, named BIO-key International ... Access Control sub-category Biometrics. , (Logo: ...
... , , , , ... states are spending more on protecting their borders, which ... trafficking. High investment in advanced technology security and IT-based ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , New analysis from Frost & ...
... As soon as babies are born, they are susceptible ... For up to a month, their immune systems aren,t ... often minor, they can lead to serious problems if ... of Missouri researchers have pinpointed a group of depleted ...
Cached Biology News:BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Researchers work on vaccine to improve immune system in newborns 2
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Nucleobindin 1 [NUCB1]...
Request Info...
... cells (HSC) are well-characterized tissue-specific stem cells ... responsible for the life-long maintenance of the ... reside in adult bone marrow where hematopoiesis ... be found in cord blood, fetal liver, ...
Biology Products: